BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 9069288)

  • 1. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.
    Su WC; Kitagawa M; Xue N; Xie B; Garofalo S; Cho J; Deng C; Horton WA; Fu XY
    Nature; 1997 Mar; 386(6622):288-92. PubMed ID: 9069288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.
    Lievens PM; Liboi E
    J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells.
    Nowroozi N; Raffioni S; Wang T; Apostol BL; Bradshaw RA; Thompson LM
    Hum Mol Genet; 2005 Jun; 14(11):1529-38. PubMed ID: 15843401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
    Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
    Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
    Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
    Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
    Adar R; Monsonego-Ornan E; David P; Yayon A
    J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
    Naski MC; Wang Q; Xu J; Ornitz DM
    Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias.
    Legeai-Mallet L; Benoist-Lasselin C; Munnich A; Bonaventure J
    Bone; 2004 Jan; 34(1):26-36. PubMed ID: 14751560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of fibroblast growth factor receptor-3 (FGFR3), signal transducer and activator of transcription-1, and cyclin-dependent kinase inhibitor p21 during endochondral ossification: differential role of FGFR3 in skeletal development and fracture repair.
    Nakajima A; Shimizu S; Moriya H; Yamazaki M
    Endocrinology; 2003 Oct; 144(10):4659-68. PubMed ID: 12960068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR3 isoforms have distinct functions in the regulation of growth and cell morphology.
    Shimizu A; Takashima Y; Kurokawa-Seo M
    Biochem Biophys Res Commun; 2002 Jan; 290(1):113-20. PubMed ID: 11779141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
    Li C; Chen L; Iwata T; Kitagawa M; Fu XY; Deng CX
    Hum Mol Genet; 1999 Jan; 8(1):35-44. PubMed ID: 9887329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells.
    Johnson MR; Valentine C; Basilico C; Mansukhani A
    Oncogene; 1998 May; 16(20):2647-56. PubMed ID: 9632141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A central nervous system specific mouse model for thanatophoric dysplasia type II.
    Lin T; Sandusky SB; Xue H; Fishbein KW; Spencer RG; Rao MS; Francomano CA
    Hum Mol Genet; 2003 Nov; 12(21):2863-71. PubMed ID: 12966031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response.
    Korpelainen EI; Kärkkäinen M; Gunji Y; Vikkula M; Alitalo K
    Oncogene; 1999 Jan; 18(1):1-8. PubMed ID: 9926914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
    Khnykin D; Olsnes S
    Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data.
    Tsai FJ; Tsai CH; Chang JG; Wu JY
    Am J Med Genet; 1999 Sep; 86(3):300-1. PubMed ID: 10482885
    [No Abstract]   [Full Text] [Related]  

  • 17. Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the Golgi apparatus without translocation to the nucleus.
    Citores L; Bai L; Sørensen V; Olsnes S
    J Cell Physiol; 2007 Jul; 212(1):148-56. PubMed ID: 17311277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK.
    Koike M; Yamanaka Y; Inoue M; Tanaka H; Nishimura R; Seino Y
    J Bone Miner Res; 2003 Nov; 18(11):2043-51. PubMed ID: 14606518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid hormone receptor type 1/Indian hedgehog expression is preserved in the growth plate of human fetuses affected with fibroblast growth factor receptor type 3 activating mutations.
    Cormier S; Delezoide AL; Benoist-Lasselin C; Legeai-Mallet L; Bonaventure J; Silve C
    Am J Pathol; 2002 Oct; 161(4):1325-35. PubMed ID: 12368206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I.
    d'Avis PY; Robertson SC; Meyer AN; Bardwell WM; Webster MK; Donoghue DJ
    Cell Growth Differ; 1998 Jan; 9(1):71-8. PubMed ID: 9438390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.